-
1
-
-
31144453233
-
BRAF mutation predicts sensitivity to MEK inhibition
-
Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
-
(2006)
Nature
, vol.439
, pp. 358-362
-
-
Solit, D.B.1
Garraway, L.A.2
Pratilas, C.A.3
-
2
-
-
77949568748
-
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
-
Drosten M, Dhawahir A, Sum EY, et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J 2010, 29:1091-1104.
-
(2010)
EMBO J
, vol.29
, pp. 1091-1104
-
-
Drosten, M.1
Dhawahir, A.2
Sum, E.Y.3
-
3
-
-
0037805547
-
RAS oncogenes: the first 30 years
-
Malumbres M, Barbacid M RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 459-465
-
-
Malumbres, M.1
Barbacid, M.2
-
4
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
-
(2010)
N Engl J Med
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
-
5
-
-
84861083983
-
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
-
Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
-
(2012)
Lancet
, vol.379
, pp. 1893-1901
-
-
Falchook, G.S.1
Long, G.V.2
Kurzrock, R.3
-
6
-
-
74849109743
-
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
-
Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
-
(2010)
Cell
, vol.140
, pp. 209-221
-
-
Heidorn, S.J.1
Milagre, C.2
Whittaker, S.3
-
7
-
-
79952261716
-
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition
-
Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011, 17:989-1000.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 989-1000
-
-
Gilmartin, A.G.1
Bleam, M.R.2
Groy, A.3
-
8
-
-
84864340896
-
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
-
published online July 16.
-
Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012, published online July 16. http://dx.doi.org/10.1016/S1470-2045(12)70270-X.
-
(2012)
Lancet Oncol
-
-
Infante, J.R.1
Fecher, L.A.2
Falchook, G.S.3
-
9
-
-
84864371119
-
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
-
published online July 16.
-
Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, published online July 16. http://dx.doi.org/10.1016/S1470-2045(12)70269-3.
-
(2012)
Lancet Oncol
-
-
Falchook, G.S.1
Lewis, K.D.2
Infante, J.R.3
-
10
-
-
84863673204
-
Improved survival with MEK inhibition in BRAF-mutated melanoma
-
for the METRIC Study Group, Published online June 4.
-
Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, for the METRIC Study Group, Published online June 4. 10.1056/NEJMoa1203421.
-
(2012)
N Engl J Med
-
-
Flaherty, K.T.1
Robert, C.2
Hersey, P.3
-
11
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
-
(2012)
N Engl J Med
, vol.366
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
|